20.12
3.86%
-0.65
Schlusskurs vom Vortag:
$20.77
Offen:
$20.88
24-Stunden-Volumen:
11,332
Relative Volume:
0.05
Marktkapitalisierung:
$614.73M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-
EPS:
-
Netto-Cashflow:
$-51.44M
1W Leistung:
-21.66%
1M Leistung:
-29.64%
6M Leistung:
-18.73%
1J Leistung:
+73.64%
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
857-201-2700
Adresse
300 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie DNTH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
DNTH | 20.13 | 614.73M | 4.12M | -56.68M | -51.44M | 0.00 |
VRTX | 447.46 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 742.25 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.63 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
2024-02-15 | Eingeleitet | Stifel | Buy |
2023-12-26 | Eingeleitet | Jefferies | Buy |
2023-11-22 | Eingeleitet | Wedbush | Outperform |
2023-10-30 | Eingeleitet | Guggenheim | Buy |
2023-09-28 | Eingeleitet | Raymond James | Outperform |
2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
2021-08-20 | Fortgesetzt | Goldman | Neutral |
2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-07-22 | Bestätigt | B. Riley Securities | Buy |
2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
2021-01-07 | Eingeleitet | Mizuho | Buy |
2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat
What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat
Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World
Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga
Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat
Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World
A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap UpHere's Why - MarketBeat
Dianthus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dianthus Therapeutics Reports Q3 Progress and Financials - TipRanks
Dianthus Therapeutics Reports $342.6M Cash Runway, Advances Phase 3 CIDP Trial Plans | DNTH Stock News - StockTitan
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts - MarketBeat
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times
Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat
Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World
Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN
Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha
Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World
Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat
Expert Ratings For Dianthus Therapeutics - Benzinga
Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World
Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat
Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World
Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World
Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):